Neurological Surgery 脳神経外科42巻10号

2014年10月発行

総説

脳神経外科分野での「ユビキチン・プロテアソーム系」—タンパク質の臨床応用

著者： 道上宏之¹ 伊達勲²

所属機関： ¹岡山大学大学院医歯薬学総合研究科細胞生理学 ²岡山大学大学院医歯薬学総合研究科脳神経外科

ページ範囲：P.899 - P.906

Ⅰ．はじめに

　「ユビキチン・プロテアソーム系」という言葉を聞いて，ピンとくる方は，基礎研究から離れた臨床医の先生方には非常に少ないと思われる．それでは，ユビキチン・プロテアソーム系とは，基礎研究と関わりのない多くの臨床医・脳神経外科医にとっては，まったく関係ない別世界の話であろうか？

　本稿では，脳神経外科医の頭の片隅に少しでも残していただきたい脳神経外科分野に関連したユビキチン・プロテアソーム系，さらにそれらの先にあるタンパク質の臨床応用への方向性についてまとめた．

参考文献

1) Al-Husein B, Abdalla M, Trepte M, Deremer DL, Somanath PR：Antiangiogenic therapy for cancer：an update. Pharmacotherapy 32：1095-1111, 2012

2) Aloni-Grinstein R, Shetzer Y, Kaufman T, Rotter V：p53：The barrier to cancer stem cell formation. FEBS Lett 588：2580-2589, 2014

3) Aprile G, Ferrari L, Fontanella C, Puglisi F：Bevacizumab in older patients with advanced colorectal or breast cancer. Crit Rev Oncol Hematol 87：41-54, 2013

4) Candan G, Michiue H, Ishikawa S, Fujimura A, Hayashi K, Uneda A, Mori A, Ohmori I, Nishiki T, Matsui H, Tomizawa K：Combining poly-arginine with the hydrophobic counter-anion 4-(1-pyrenyl)-butyric acid for protein transduction in transdermal delivery. Biomaterials 33：6468-6475, 2012

5) Czyz CN, Burns JA, Petrie TP, Watkins JR, Cahill KV, Foster JA：Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome. Am J Ophthalmol 156：173-177, 2013

6) Dai C, Gu W：p53 post-translational modification：deregulated in tumorigenesis. Trends Mol Med 16：528-536, 2010

7) Derrien B, Genschik P：When RNA and prote in degradation pathways meet. Front Plant Sci 5：161, 2014

8) Devine T, Dai MS：Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy. Curr Pharm Des 19：3248-3262, 2013

9) Fujimura A, Michiue H, Cheng Y, Uneda A, Tani Y, Nishiki T, Ichikawa T, Wei FY, Tomizawa K, Matsui H：Cyclin G2 promotes hypoxia-driven local invasion of glioblastoma by orchestrating cytoskeletal dynamics. Neoplasia 15：1272-1281, 2013

10) 二木史朗：細胞膜を透過する塩基性ペプチド 蛋白質・薬物の細胞内導入への可能性．蛋・核・酵 47：1415-1419, 2002

11) Goh AM, Coffill CR, Lane DP：The role of mutant p53 in human cancer. J Pathol 223：116-126, 2011

12) Hershko A：The ubiquitin system for protein degradation and some of its roles in the control of the cell-division cycle（Nobel lecture). Angew Chem Int Ed Engl 44：5932-5943, 2005

13) Inobe T, Matouschek A：Paradigms of protein degradation by the proteasome. Curr Opin Struct Biol 24：156-164, 2014

14) Inoue K, Kurabayashi A, Shuin T, Ohtsuki Y, Furihata M：Overexpression of p53 protein in human tumors. Med Mol Morphol 45：115-123, 2012

15) Khafagy el-S, Morishita M：Oral biodrug delivery using cell-penetrating peptide. Adv Drug Deliv Rev 64：531-539, 2012

16) Li C, Xiao ZX：Regulation of p63 protein stability via ubiquitin-proteasome pathway. Biomed Res Int 2014：175721, 2014

17) Lopes LB, Furnish E, Komalavilas P, Seal BL, Panitch A, Bentley MV, Brophy CM：Enhanced skin penetration of P20 phosphopeptide using protein transduction domains. Eur J Pharm Biopharm 68：441-445, 2008

18) Matsushita M, Tomizawa K, Moriwaki A, Li ST, Terada H, Matsui H：A high-efficiency protein transduction system demonstrating the role of PKA in long-lasting long-term potentiation. J Neurosci 21：6000-6007, 2001

19) Michiue H, Tomizawa K, Matsushita M, Tamiya T, Lu YF, Ichikawa T, Date I, Matsui H：Ubiquitination-resistant p53 protein transduction therapy facilitates anti-cancer effect on the growth of human malignant glioma cells. FEBS Lett 579：3965-3969, 2005

20) 中瀬生彦，二木史朗：細胞膜ペプチドベクターの開発とメカニズム．生化学 81：992-995, 2009

21) Nguyen AT, Ahmad J, Fagien S, Rohrich RJ：Cosmetic medicine：facial resurfacing and injectables. Plast Reconstr Surg 129：142e-153e, 2012

22) Ookubo N, Michiue H, Kitamatsu M, Kamamura M, Nishiki T, Ohmori I, Matsui H：The transdermal inhibition of melanogenesis by a cell-membrane-permeable peptide delivery system based on poly-arginine. Biomaterials 35：4508-4516, 2014

23) Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D, Casanovas O：Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15：220-231, 2009

24) Pavlidis ET, Pavlidis TE：Role of bevacizumab in colorectal cancer growth and its adverse effects：a review. World J Gastroenterol 19：5051-5060, 2013

25) Qian Y, Chen X：Senescence regulation by the p53 protein family. Methods Mol Biol 965：37-61, 2013

26) Rothbard JB, Garlington S, Lin Q, Kirschberg T, Kreider E, McGrane PL, Wender PA, Khavari PA：Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat Med 6：1253-1257, 2000

27) Royds JA, Iacopetta B：p53 and disease：when the guardian angel fails. Cell Death Differ 13：1017-1026, 2006

28) Shih T, Lindley C：Bevacizumab：an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28：1779-1802, 2006

29) Soda Y, Myskiw C, Rommel A, Verma IM：Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme. J Mol Med（Berl）91：439-448, 2013

30) Takayama K, Tadokoro A, Pujals S, Nakase I, Giralt E, Futaki S：Novel system to achieve one-pot modification of cargo molecules with oligoarginine vectors for intracellular delivery. Bioconjug Chem 20：249-257, 2009

31) Yukawa H, Noguchi H, Nakase I, Miyamoto Y, Oishi K, Hamajima N, Futaki S, Hayashi S：Transduction of cell-penetrating peptides into induced pluripotent stem cells. Cell Transplant 19：901-909, 2010

32) Zagzag D, Lukyanov Y, Lan L, Ali MA, Esencay M, Mendez O, Yee H, Voura EB, Newcomb EW：Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma：implications for angiogenesis and glioma cell invasion. Lab Invest 86：1221-1232, 2006

33) Zhou H, Wu S, Joo JY, Zhu S, Han DW, Lin T, Trauger S, Bien G, Yao S, Zhu Y, Siuzdak G, Schöler HR, Duan L, Ding S：Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 4：381-384, 2009